赛隆药业(002898) - 2018 Q3 - 季度财报

Financial Performance - Operating income for the reporting period was ¥96,144,995.85, a decrease of 9.69% year-on-year, while year-to-date revenue increased by 30.47% to ¥325,467,888.33[8] - Net profit attributable to shareholders for the reporting period was ¥12,854,455.15, down 10.73% year-on-year, with a year-to-date net profit of ¥47,340,668.38, reflecting a slight increase of 0.87%[8] - Basic earnings per share for the reporting period were ¥0.0803, down 10.78% year-on-year, while diluted earnings per share remained the same[8] - The company expects net profit attributable to shareholders for 2018 to be between ¥55.48 million and ¥71 million, a decrease of 13.99% to 10.07% compared to the previous year[20] Assets and Liabilities - Total assets at the end of the reporting period reached ¥736,528,894.49, an increase of 2.99% compared to the end of the previous year[8] - The company's cash and cash equivalents decreased by 49.95% to ¥184,285,171.96 due to investments in production and marketing projects[16] - Accounts receivable increased by 111.25% to ¥104,729,994.88 as a result of market expansion and sales growth[16] - The company's inventory increased by 73.43% to ¥47,215,284.54 to adapt to market changes[16] - Deferred tax assets rose by 203.46% to ¥6,813,598.49 due to temporary differences in accounting and tax standards[16] Cash Flow - The net cash flow from operating activities was ¥6,889,502.10, a significant increase of 241.35% compared to the same period last year[8] Shareholder Information - The total number of shareholders at the end of the reporting period was 23,560, with the top ten shareholders holding a combined 81.15% of the shares[12] - The largest shareholder, Cai Nanguai, holds 51.15% of the shares, totaling 81,833,579 shares[12] - The company did not engage in any repurchase transactions during the reporting period[13] - The company has no overdue commitments from shareholders or related parties during the reporting period[18] Expenses and Investments - Operating costs rose by 89.61% to ¥141,932,368.61, driven by the increase in sales scale[17] - Research and development expenses decreased by 50.97% to ¥7,671,397.98 as projects entered the development phase[17] - The company invested significantly in fixed assets, with cash payments for acquisitions increasing by 168.65% to ¥99,117,876.64[17] Government Support - The company received government subsidies amounting to ¥1,567,358.90 during the year-to-date period[9] Return on Investment - The weighted average return on net assets was 1.97%, a decrease of 1.27% compared to the previous year[8]